TABLE 2.
Comparative Outcomes
| Regimen | Second Line | Third Line (All Comparators) | Third Line (PAN-BOR-DEX Omitted) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cost, $ | QALYs | ICER | Total Cost, $ | QALYs | ICER | Total Cost, $ | QALYs | ICER | |
| LEN-DEX | 309,997 | 2.59 | Dominated | 281,754 | 2.04 | Dominated | 281,754 | 2.04 | Dominated |
| BOR-DEX | 189,357 | 2.74 | Dominant | 175,315 | 2.16 | Dominant | 175,315 | 2.16 | Dominant |
| IX-LEN-DEX | 622,378 | 3.27 | Dominated | 566,512 | 2.60 | Dominated | 566,512 | 2.60 | Dominated |
| ELO-LEN-DEX | 665,728 | 3.41 | Dominated | 608,651 | 2.71 | Dominated | 608,651 | 2.71 | Dominated |
| CFZ-LEN-DEX | 492,872 | 3.45 | Dominated | 459,868 | 2.74 | Dominated | 459,868 | 2.74 | Dominated |
| PAN-BOR-DEX | 190,876 | 3.23 | 14,598 | ||||||
| DAR-BOR-DEX | 447,182 | 5.29 | 50,704 | 423,119 | 4.38 | 248,762 | 423,119 | 4.38 | 60,359 |
| DAR-LEN-DEX | 845,527 | 5.44 | 2,707,547 | 789,202 | 4.38 | Equal outcomes, higher cost vs. DAR-BOR-DEX | 789,202 | 4.38 | Equal outcomes, higher cost vs. DAR-BOR-DEX |
BOR = bortezomib; CFZ = carfilzomib; CPT = Current Procedural Terminology; DAR = daratumumab; DEX = dexamethasone; ELO = elotuzumab; IX = ixazomib; LEN = lenalidomide; OS = overall survival; PAN = panobinostat; PFS = progression-free survival; QALY = quality-adjusted life-year.